Monday, October 7, 2019

Journal 3: Probiotics Improve Inflammation-Associated Sickness Behavior by Altering Communication between the Peripheral Immune System and the Brain


This paper introduces a novel pathway that may be involved Inflammation-Associated sickness behaviors. The periphery-to-brain communication pathway is described as bowel inflammation causing TNF-alpha signaling, followed by microglia activation and monocyte infiltration into the brain vasculature add parenchyma, which then results in the development of sickness behaviors. Past studies have shown that probiotics aimed to teat bowel-irritation has also improve sickness behaviors related to it. D’Mello et al. then investigated if probiotics ingestion can alter this pathway and reduced sickness behaviors.
D’Mello et al. studies their hypothesis but using mice with liver inflammation due to bile duct ligation (BDL). They established that BDL mice have increased sickness behaviors than sham controlled mice through decreased social exploration found in BDL mice. Next they administered VSL#3 treatment (a probiotic) to BDL mice and tested to see changes in sickness behaviors and gut microbiome compared to controls. This did not change the microbiome compared to sham mice and it significantly improve sickness behaviors in BDL mice. To further test the pathway that may be involved in this sickness behaviors, the authors studied how VSL#3 alters systemic immunity and inflammatory monocyte recruitment to the brain in BDL mice. This treatment showed an increase in cytokines in BDL mice, increased G-CSF, and decrease TNF-alpha signaling in BDL mice. Sickness behaviors however were not different between treated VSL#3 BDL mice and vehicle treated BDL mice. The authors further tested microglia activation changes in treated VSL#3 BDL mice and vehicle treated BDL mice. VSL#3 treated BDL mice showed more resting microglia and decreased number of activated microglia and activated microglia expressing TNF-alpha. The same results were shown in BDL mice treated with etanercept which inhibits TNF-alpha. Lastly, monocyte infiltration was studied. VSL#3 treatment reduced number of monocyte infiltration and number of TNF-alpha-expressing monocytes and the same results were found in BDL mice treated with etanercept.
These results show that VSL#3 treatment does alter periphery-to-brain communication pathway and improves sickness behaviors but does not necessarily link these to findings together. This may mean that VSL#3 treatment may take part in improving sickness behaviors by altering a different pathway and periphery-to-brain communication pathway may be involved in a different symptom caused by irritable bowel syndrome. Additionally, it is unclear how VSL#3 leads to changes in systemic immunity since the gut microbiome was not changed in treated mice. More studies need to be done to find other pathways involved in sickness behaviors such as vagal afferent signaling and how probiotics change systemic immunity. Lastly, the subjects in this study were all male mice. These future studies should aim to include female mice since they may have differences in sickness behaviors and gut microbiome.
I overall liked this paper because it attempted to the mechanisms behind sickness behaviors and attempted to find a treatment that could improve sickness behaviors. The paper provided more insight on a pathway that may cause sickness behaviors and found improvements with a probiotic. This may pave way for more studies to find potential probiotic treatments for neuropsychiatric disorders.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.